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ABSTRACT 1 
Cardiopulmonary bypass (CPB) during heart surgery is a well-known cause of hematologic dysfunction 2 
in the postoperative period and has been linked to a higher incidence of bleeding and platelet 3 
disturbances. Little is however known concerning the postoperative platelet profile. The aim of our study 4 
was to analyze the platelet count evolution in a pediatric population before and until the 10
th
 postoperative 5 
day after cardiac procedures and to relate this evolution with pre-, intra- and post-operative factors. We 6 
used a retrospective design to analyze the medical records of 68 patients admitted to our Pediatric 7 
Intensive Care Unit. 51.8% patients subjected to CPB developed thrombocytopenia postoperatively. In 8 
patients with CPB platelet count fell sharply on postoperative day 1 and continued falling until day 5, 9 
when it reached a nadir, steadily increasing from that day onwards. Postoperative thrombocytopenia was 10 
significantly related to intraoperative CPB (p=0.001), aorta cross-clamp (p=0.003) and surgery duration 11 
(p<0.001) as well as plasma transfusion (p=0.023). Conclusion: a steep decrease in platelet count is to be 12 
expected after surgery and until 5 days postoperatively, which might be of great value for physicians 13 
working with children in the postoperative period, helping them to assess the severity of platelet levels 14 
and to make appropriate clinical decisions. 15 
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“WHAT IS KNOWN – WHAT IS KNEW” 25 
Cardiopulmonary bypass (CPB) during heart surgery is a well-known cause of hematologic dysfunction 26 
in the postoperative period and has been linked to a higher incidence of bleeding and platelet 27 
disturbances. 28 
We found out that in patients being submitted to heart surgery with cardiopulmonary bypass the platelet 29 
count has a steep decrease in the 1
st
 postoperative day, continuing to decrease until the 5
th
 postoperative 30 
day. 31 
 32 
 33 
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 39 
 40 
 41 
 42 
 43 
 44 
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INTRODUCTION 46 
Congenital heart defects are the most common type of birth defects. A recent systematic review found the 47 
worldwide incidence of these defects to be 9.1/1000 live births and 8/1000 in Europe [1]. The advent of 48 
extracorporeal techniques such as cardiopulmonary bypass (CPB) largely improved the possibility for 49 
these defects to be surgically corrected but despite improving significantly the long-term prognosis of 50 
these children [2] it is still a major cause of hemostatic and inflammatory disturbances [3]. These are even 51 
more pronounced in the pediatric setting due to their immature hemostatic system, congenital heart 52 
disease, surgical complexity and reduced blood volume [2]. CPB has been linked to a steep decrease in 53 
coagulation factor levels and platelet counts [4, 5] and to a significant increase in the incidence of 54 
bleeding [2,3,6,7] and need for blood product transfusions [2,7-9]. 55 
Different studies have addressed platelet behaviour [10-13]. Nonetheless, contradictory results referring 56 
to platelet function during CPB have been observed during the pre- and intra-operative periods, with 57 
studies pointing to platelet hyporeactivity [13], others to an increase in platelet activity [10,12] and even 58 
others to variable responses, with some patients experiencing an increase while others suffer a decrease in 59 
platelet aggregability [11]. Regarding platelet count variations have also been reported during the same 60 
operative period and several studies described a steep decrease in platelet count immediately after CPB 61 
initiation [4,5,10-13], as high as 71% [4,13], remaining throughout the procedure. 62 
Little is however known about these aspects during the postoperative period. Platelet function is not 63 
routinely assessed and therefore, routine retrospective data are difficult to acquire. On the other hand, 64 
platelet count can be easily recorded. Nevertheless, few studies comprising the postoperative period have 65 
been conducted [5,11,14]. A postoperative decrease in platelet count might have an infectious or 66 
hemorrhagic cause. Hence, information on platelet behaviour postoperatively could permit a better 67 
judgment on when a decrease in platelet count should or should not be expected and, consequently, to act 68 
accordingly. 69 
Therefore, this study aimed to describe the platelet count and identify the incidence of thrombocytopenia, 70 
preoperatively and until the 10th postoperative day, and to explore possible relations with pre-, intra- and 71 
post-operative factors. 72 
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METHODS 73 
This was a retrospective study approved by the Institutional Review Board who waived the need for 74 
parental informed consent. 75 
Medical records of all children immediately admitted to a Pediatric Intensive Care Unit (PICU) of a 76 
tertiary hospital in Oporto, Portugal, after being submitted to a cardiac procedure for a congenital heart 77 
defect between January 1, 2013 to December 31, 2013 were selected and analyzed. Records from children 78 
aged <28 days were excluded from the study. The number of patients entering the PICU after heart 79 
surgery during the study period determined the sample size. 80 
Data were collected from three different places. Patient’s hospital records were used for preoperative 81 
data, anesthesia and perfusion flow sheets for intraoperative data and intensive care unit records for 82 
postoperative data. 83 
Data on preoperative variables like age, gender, weight and main diagnosis were collected. Intraoperative 84 
data comprised type and duration of surgery, plasma, erythrocytes or platelets transfusion and, when 85 
applicable, the value of hypothermia, duration of CPB and aortic cross-clamp and Risk Adjustment for 86 
Congenital Heart Surgery (RACHS-1) score. Postoperative factors analyzed included PICU and hospital 87 
length of stay, the presence or absence of hypothermia, administration of heparin, furosemide, 88 
sympathomimetic amines or antibiotics and the need of dialysis or the transfusion of blood products.  89 
Not only the platelet count for each postoperative day was analyzed as we also categorized this variable 90 
for the presence or not of thrombocytopenia, <100 000/mm
3
 or ≥100 000/mm3, respectively. 91 
Thrombocytopenia was evaluated in each postoperative day and as its global occurrence in the 92 
postoperative period. Patients were also divided in two groups respective to the presence or absence of 93 
CPB during surgery. 94 
Both thrombocytopenia and CPB were compared to pre-, intra- and post-operative variables. Mann-95 
Whitney test was used for continuous parameters and categorical variables were analyzed with the Qui-96 
Square and Fisher tests. A p value less than 0.05 was considered significant. Data processing and analyses 97 
were performed with SPSS 20.0 software (SPSS Inc, Chicago, IL). 98 
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RESULTS 99 
During 2013 there were 91 entrances in the PICU after cardiac procedures. From these 3 patients 100 
underwent a pacemaker-related intervention or pericardiocentesis, 7 had surgery for a heart transplant, 101 
rheumatic or infectious diseases, 2 patients went to the Cardiothoracic Surgery Unit in the immediate 102 
postoperative period due to an impossibility of chest closure, 1 patient died shortly after surgery and 10 103 
medical records were unavailable and were therefore excluded. At the end 68 medical records were 104 
analyzed with 56 (82,4%) with CPB. Patients’ demographic and perioperative information is summarized 105 
in Table 1. 106 
When compared to patients submitted to surgery without CPB, those undergoing surgery with CPB 107 
required more postoperative transfusions (39.3 vs 8.3%, p=0.048) and had a higher incidence of post-108 
surgery thrombocytopenia (51.8 vs 8.3%, p=0.006) (Table 2). Newly developed thrombocytopenia was 109 
41% for all children and 49.9% for the CPB group. Postoperative complications as renal failure or 110 
infection showed no relation to CPB procedure. No significant difference was found regarding 111 
preoperative platelet values in both groups. However, after surgery, there was a steep decrease on platelet 112 
count, significantly more pronounced in the CPB group, reaching a nadir on postoperative day 5, 113 
increasing from that day onwards (Figure 1), which occurred irrespective of patients’ age category (data 114 
not shown). 115 
From the 64 patients with preoperative platelets count, 2 (3.1%) had preoperative thrombocytopenia. On 116 
the other hand, during the postoperative period 30 (44.1%) patients developed thrombocytopenia. 117 
Postoperative thrombocytopenia was significantly correlated to intraoperative factors such as aorta cross-118 
clamp (p=0.003), CPB (p=0.001) and surgery duration (p<0.001), plasma transfusion (p=0.023) and 119 
RACHS-1 score (p=0.02) and to postoperative parameters such as the need for induced hypothermia 120 
(p=0.004), peritoneal dyalisis (p=0.034), blood transfusion (p<0.001) and sympathomimetic amines 121 
support (p=0.009) but not to infection (p=0.088) (Table 3). Thrombocytopenia was not significantly 122 
related to patients’ gender, age or weight. Nor CPB employment or postoperative thrombocytopenia had a 123 
significant relation with PICU and hospital length of stay. 124 
 125 
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DISCUSSION 126 
Analyzing the platelet count after surgery we observed that for patients being submitted to CPB the 127 
median platelet count had a 49.4% decrease in the 1
st
 postoperative day. On the contrary, those not being 128 
submitted to CPB had a 6.5% increase in the 1
st
 postoperative day decreasing from that day onwards. The 129 
platelet profile followed a similar pattern on both groups, keeping significantly higher values in the non-130 
CPB group. We found an incidence of newly developed thrombocytopenia of 41% globally and of 49.9% 131 
in the CPB group, similar to the value of 54.3% reported by others [14]. This decrease on platelet values 132 
might be due to hemodilution, contact activation of the hemostatic system or to the systemic 133 
inflammatory response after CPB [2,6] and has been observed in other studies [5,11,12]. 134 
CPB is a well-known cause of hemostatic dysfunction causing marked platelet disturbances during 135 
surgery [4,5,10,12,13] and increasing the postoperative risk for bleeding [2,8,11]. Ignjatovic V and 136 
colleagues [10] observed a marked decrease in platelet count accompanied by an increase in their activity 137 
during CPB procedures in children up to 6 years. Accordingly Ranucci M and associates [11] describe a 138 
diminution in platelet count until the 2
nd
 postoperative day with variable platelet aggregability behaviour 139 
in patients until 4 years old. Karagöl B et al [14] went further on the postoperative period studying the 140 
platelet count until the 7
th
 postoperative day, both in children with and without Down syndrome. They 141 
observed a marked decrease on platelet levels after surgery which persisted until the 3
rd
 postoperative day 142 
starting to increase afterwards, albeit not reaching the preoperative values by the end of the study period. 143 
In our study patients undergoing CPB had a reduction of platelet values which persisted until 5 days after 144 
surgery, raising thereafter, still not reaching baseline values by the 10
th
 postoperative day. However, late 145 
platelet values might be underestimated since analyses were only obtained for patients with a longer 146 
hospitalization period, which might comprise those with worst postoperative evolution with consequent 147 
lower platelet values. Additionally, patients not undergoing CPB had a sustained increase in platelet count 148 
after the 6
th
 postoperative day and exceeded baseline values 8 days after surgery. 149 
Postoperative thrombocytopenia showed a significant relation to other postoperative complications as the 150 
need for dyalisis, transfusion, hypothermia and sympathomimetic support. It was also correlated to CPB, 151 
aortic cross-clamp and surgery duration and intraoperative plasma transfusion, which is in accordance to 152 
previous findings [14]. Although CPB procedure significantly correlated to post-surgery 153 
thrombocytopenia we found no such relation to the previously stated postoperative complications. 154 
7 
 
Some limitations of this study need to be acknowledged. First, we had to restrict platelet count 155 
information to days where analyses had been ordered instead of getting daily values and not every patient 156 
had the same hospital length of stay so, as days went by, fewer patients had analyses values which 157 
diminished the strength of the results. Nevertheless, we were able to obtain statistically significant 158 
differences between CPB procedure groups for most of postoperative days. Second, the reduced number 159 
of records analyzed with only 12 cases referring to non-CPB procedures caused statistically significant 160 
differences between both groups harder to achieve. Third, although postoperative thrombocytopenia has 161 
consistently been related to patient’s age and weight [2,11], the limited number of our study population 162 
may have hampered this relationship. 163 
We were only able to find one study addressing platelet evolution in the postoperative period and it was 164 
focused on children with Down syndrome [14]. Since thrombocytopenia is an important cause of 165 
morbidity during this period, information regarding platelet count profile may be of much value. 166 
Physicians working with children after heart surgery might find themselves uncertain of what to do in the 167 
presence of low platelet counts. Therefore, information on what is to be expected in this period may be 168 
very important to assess the severity of platelet levels and to make appropriate clinical decisions. 169 
In conclusion, we found out that cardiac surgery seems to cause a marked decrease in platelet count, 170 
which is significantly more accentuated in the CPB group that is sustained over time and starts to increase 171 
only after the 5
th
 postoperative day.  172 
 173 
 174 
 175 
 176 
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TABLES AND FIGURES 227 
 228 
Table 1 – Patient demographic and perioperative variablesa 229 
 230 
 231 
 232 
 233 
 234 
 235 
 236 
 237 
 238 
 239 
 240 
a
 Values presented as median (interquartile range)* or number (percentage)# 241 
 242 
 243 
 244 
 245 
Variable Value 
Age (years)
*
 2 (1.1-7.8) 
Weight (kg)
*
 12.5 (8.6-22.5) 
Male gender
#
 39 (57.4) 
Operation time (min)
*
 279 (182-378) 
Surgery with CPB
#
 56 (82.4) 
  CPB time (min)
*
 117 (57-172) 
  Cross-clamp time (min)
*
 65 (34-96) 
  Temperature, minimum ºC
*
 34 (32-35) 
RACHS-1 score 
  Undefined
#
 
  1
#
 
  2
#
 
  3
#
 
  4
#
 
  5/6
#
 
 
8 (11.8) 
16 (23.5) 
24 (35.3) 
17 (25) 
2 (2.9) 
0 (0) 
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Table 2 – Postoperative parameters from patients with and without intraoperative 246 
cardiopulmonary bypass (CPB)a 247 
Variable CPB group (N=56) Non-CPB group 
(N=12) 
P 
value 
 
PICU length of stay* 
Hospital length of stay* 
Postoperative use of 
  Sympathomimetic amines# 
  Furosemide# 
  Antibiotics change# 
  Dyalisis# 
  Blood products transfusion# 
  Hypothermia# 
 
4 (3-7) 
8 (7-14) 
 
28 (50) 
54 (96.4) 
12 (21.4) 
4 (7.1) 
22 (39.3) 
14 (25.5) 
 
4 (4-7) 
7 (6-9) 
 
3 (25) 
10 (83.3) 
2 (16.7) 
0 (0) 
1 (8.3) 
0 (0) 
 
0.908 
0.350 
 
0.115 
0.141 
1 
1 
0.048 
0.058 
Postoperative thrombocytopenia# 29 (51.8) 1 (8.3) 0.006 
    
 248 
a
Values presented as median (interquartile range)* or number (percent of column population)# 249 
 250 
 251 
 252 
 253 
 254 
 255 
 256 
 257 
 258 
 259 
 260 
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Table 3 – Pre-, intra- and post-operative parameters from patients with and without postoperative 261 
thrombocytopenia
a
 262 
Variable Nonthrombocytopenic 
cases (N=38) 
Thrombocytopenic 
cases (N=30) 
P value 
Age (years)
*
 2.5 (1-8) 1.88 (1-7) 0.916 
Weight (kg)
*
 14.8 (8-23) 12 (8.9-21) 0.961 
Male gender 
#
  22 (58) 17 (57) 0.919 
Operation time (min)
*
 195 (157-279) 349 (286-449) <0.001 
Intraoperative plasma transfusion
#
 
Intraoperative erythrocyte transfusion
#
 
Intraoperative platelet transfusion
#
 
Surgery with CPB 
10 (31) 
9 (28) 
12 (36) 
27 (71) 
18 (60) 
8 (27) 
16 (53) 
29 (97) 
0.023 
0.898 
0.176 
0.006 
  CPB time (min)
*
 
  Cross-clamp time (min)
*
 
  Temperature, minimum ºC
*
 
76 (49-111) 
51 (22-70) 
34 (0-35) 
156 (117-186) 
77 (62-116) 
34 (32-34) 
0.001 
0.003 
0.435 
RACHS-1 score
#
 
  Undefined
#
 
  1
#
 
  2
#
 
  3
#
 
  4
#
 
  5/6
# 
PICU length of stay
*
 
Hospital length of stay
*
 
 
1 (3) 
12 (35) 
9 (27) 
12 (35) 
0 (0) 
0 (0) 
4 (3-7) 
7 (6-10) 
 
0 (0) 
4 (15) 
15 (58) 
5 (19) 
2 (8) 
0 (0) 
5 (3-9) 
8 (7-16) 
0.020 
 
 
 
 
 
 
0.081 
0.414 
Postoperative use of 
  Sympathomimetic amines
#
 
  Furosemide
#
 
  Antibiotics change
#
 
 
12 (32) 
34 (90) 
5 (13) 
 
19 (63) 
30 (100) 
9 (30) 
 
0.009 
0.124 
0.088 
13 
 
  Dyalisis
#
 
  Blood products transfusion
#
 
  Hypothermia
#
 
0 (0) 
3 (8) 
3 (8) 
4 (13) 
20 (67) 
11 (37) 
0.034 
<0.001 
0.004 
    
a
 Values presented as median (interquartile range)* or number (percent of column population)# 263 
 264 
 265 
 266 
 267 
  268 
 269 
 270 
 271 
 272 
 273 
 274 
 275 
Figure 1 – Median platelet count preoperatively and during the postoperative period 276 
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